Insilico Medicine & Eli Lilly Forge Strategic AI‑Driven Drug Discovery Alliance
Insilico Medicine, a leader in artificial‑intelligence‑powered drug discovery, today announced a strategic collaboration with Eli Lilly (NYSE:...
Insilico Medicine
China’s Insilico, Mabwell, and Chemexpress Forge AI‑Driven ADC Collaboration
Insilico Medicine, a global leader in generative AI‑driven drug discovery, announced a strategic partnership with...
Insilico Medicine Partners with UAEU to Drive Biotech Innovation in the Middle East
China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine this week entered into a strategic Memorandum...
Insilico Medicine Files for IPO to Leverage AI in Drug Discovery
China-based Insilico Medicine, a biotech company leveraging generative artificial intelligence (AI), has filed for an...
Insilico Medicine Collaborates with Mabwell Bio to Enhance ADC R&D with AI
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has entered into a collaboration with compatriot...
Insilico Medicine Closes USD110 Million Series E Round to Advance AI-Driven Drug Pipeline
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine announced the completion of a USD110 million...
Insilico Medicine’s AI-Discovered Drug Rentosertib Approved for Clinical Trials
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine announced approval by the United States Adopted...
Insilico Medicine and Tenacia Partner on AI-Driven CNS Therapies
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has formed a partnership with compatriot firm...
Harbour BioMed and Insilico Medicine Partner on AI-Powered Antibody Development
China-based Harbour BioMed (HKG: 2142) announced a strategic partnership with Insilico Medicine, a generative artificial...
Insilico Medicine Raises USD 100 Million in Financing Round Led by Pudong and Hong Kong
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has reportedly raised USD 100 million in...
Insilico Medicine’s ISM5411 Shows Positive Results in Phase I Studies for Inflammatory Bowel Disease
China’s generative artificial intelligence (AI)-driven biotech, Insilico Medicine, has announced positive preliminary results from two...
Insilico Medicine Receives $10 Million Milestone Payment for XL309 Clinical Progress
Chengdu-based, generative artificial intelligence (AI)-driven clinical stage biotech company, Insilico Medicine, has announced the receipt...
Insilico Medicine Gets FDA Approval for Clinical Study of ENPP1 Inhibitor ISM5939
China’s generative artificial intelligence (AI)-driven biotech company, Insilico Medicine, has announced that it has received...
Insilico Medicine Secures Revolving Loan Facility with HSBC to Boost Drug Discovery Pipeline
China-based artificial intelligence (AI) drug developer Insilico Medicine has announced the establishment of a Revolving...
Insilico Medicine and Seto Biopartner to Leverage AI in Synthetic Biology and Drug Discovery
Insilico Medicine has announced a strategic partnership with Seto Bio (SHE: 300583) to harness cutting-edge...
Insilico Medicine’s AI-Generated Drug Candidate ISM001-055 Shows Positive Phase II Results in IPF Study
China-based artificial intelligence (AI) drug developer Insilico Medicine has reported initial positive data from its...
Insilico Medicine Partners with Inimmune Corporation to Utilize AI for Immunotherapy Innovation
Insilico Medicine, a leading artificial intelligence-driven drug discovery company based in China, has announced a...
Insilico Medicine’s ISM6331 Earns FDA Orphan Drug Designation for Mesothelioma Treatment
Insilico Medicine, a China-based biotechnology company at the forefront of generative artificial intelligence (AI), has...
AI-Powered Biotech Insilico Medicine Initiates Phase I Clinical Trial for Inflammatory Bowel Disease Drug
Insilico Medicine, a China-based biotechnology company at the forefront of generative artificial intelligence (AI), has...
Insilico Medicine’s ISM8207 Enters Phase I Clinical Trial for Lymphoma and Solid Tumors
China’s generative artificial intelligence (AI)-driven biotech firm, Insilico Medicine, has announced the first patient dosing...